论文部分内容阅读
原发性硬化性胆管炎(PSC)是一种慢性淤胆性肝病,以肝内外胆管的炎症和纤维化为特征,常伴发溃疡性结肠炎。其病因不明,尽管有报道与免疫应答的改变有关,但这些异常改变是与本病的发病直接相关,还是一种继发现象尚不清楚。目前尚无治疗 PSC 的有效药物。由于 PSC 可能由免疫机制引起,试用皮质类固醇激素治疗,但病例及随访均有限。最近有人用秋水仙碱治疗原发性胆汁性肝硬化,据说该药能抑制纤维组织生成,因此用以治疗 PSC 的设想是合乎逻辑的并值得评价。
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the extrahepatic bile ducts, often associated with ulcerative colitis. The etiology is unknown. Although reports have been reported on the changes of the immune response, whether these abnormal changes are directly related to the pathogenesis of this disease or not is a secondary phenomenon. There is currently no effective medication for PSC. Since PSC may be caused by immune mechanisms, trials of corticosteroid therapy, but the cases and follow-up are limited. The recent use of colchicine in the treatment of primary biliary cirrhosis, which is said to inhibit fibrogenesis, is therefore logical and deserves evaluation for the treatment of PSC.